1 / 27

TRACK B RAPPORTEUR REPORT

TRACK B RAPPORTEUR REPORT. JOSE R ARRIBAS on behalf of …. WHEN TO START. HPTN-052. STARTING > 350 vs <250 (229). AIDS + Non-AIDS: No difference AIDS: better (TB) >500 better than < 350 ?. Grinsztejn . THLBB05. WHAT TO START. SPRING-2. Raffi . THLBB04.

ashlyn
Download Presentation

TRACK B RAPPORTEUR REPORT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TRACK B RAPPORTEUR REPORT JOSE R ARRIBAS onbehalfof…

  2. WHEN TO START

  3. HPTN-052 STARTING > 350 vs <250 (229). AIDS + Non-AIDS: No difference AIDS: better (TB) >500 betterthan < 350 ? Grinsztejn. THLBB05

  4. WHAT TO START

  5. SPRING-2 Raffi. THLBB04

  6. DOLUTEGRAVIR QD NEW OPTION NO RESISTANCE “UNPRECEDENTED” • No difference by NUCsorhigh viral loads • No INI mutationsnor NRTI mutationsweredetectedthrough 48 weekson DTG • No withdrawalsdueto renal events • Smallincrease in creatinineduetoblockadeofCrsecretion in DTG arm Raffi. THLBB04

  7. DOLUTEGRAVIR POSSIBLE FOR TEEN/KIDS (RALTEGRAVIR ALSO) “CHEWING” RAL Hazra. TUAB0203

  8. Gallant. TUAB0103

  9. COBI AND RITONAVIR CAN YOU SPOT THE DIFFERENCES? • No developmentof PI resistance in eithergroup. Similar lipids • Expectedsmallincrease in serumcreatinine (≈0.1 mg/dL) Iinthe COBI arm • Low and comparable discontinuationratesdueto renal AE • Similar discontinuationratesduetobilirubin-relatedAEs Gallant. TUAB0103

  10. HOW TO SWITCH

  11. FTC/RPV/TDF Strong/simple switch option • Lowerrateofvirologic non-suppression in FTC/RPV/TDF (17/17 withtransmitted K103N suppressed) • Switching: improvement in fastinglipidsand 10-year Framingham RiskScore Palella. TUAB0104

  12. In thesethree ARV trials < 15% females. Weneedto do better!

  13. RESISTANCE

  14. Transmitted HIVDR (WHO surveys) Relationship between transmitted resistance to NNRTI and ART coverage MORE COVERAGE, MORE OPTIONS, more (different) resistance Bertagnolio. TUAB0305

  15. TB

  16. Do notsupportweight-basedincreaseof EFV duringrifampintreatment % < 400 copies/mL EFAVIRENZ C min Luetkemeyer. TUAB0104

  17. RAL newoptionfor ART during TB treatment. Optimal RAL doseyetto be defined N. De Castro. THLBB01

  18. HCV

  19. Despite ART, HIV/HCV ptshadhigherriskofhepaticdecompensationthan HCV-monoinfectedpts Lo Re. WEAB0102

  20. AGING/COMORBIDITIES

  21. Comorbidities more prevalentamongstHIV-positives comparedtouninfectedcontrolsof similar age Schouten. THAB0205

  22. Deathrates in peoplewithaccesstocare AIDS stillleading cause ofdeath Non AIDS cancersleading non-AIDS cause ofdeath Schouten. THAB0205

  23. ADJUSTING TO TIME

  24. ADJUSTING TO SPACE

More Related